BioRestorative Therapies IncNASDAQ:BRTX
- LAST PRICE1.2300
- TODAY'S CHANGE (%)-0.0400 (-3.1496%)
- Bid / Lots1.2100/ 10
- Ask / Lots1.2600/ 5
- Open / Previous Close1.2300 / 1.2700
- Day Range
- 52 Week Range
- Volume61,996
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BRTX |
|---|---|---|
| 09:32 ET | 2521 | 1.2301 |
| 09:34 ET | 800 | 1.23 |
| 09:36 ET | 2626 | 1.2591 |
| 09:38 ET | 200 | 1.2598 |
| 09:39 ET | 2200 | 1.26 |
| 09:43 ET | 127 | 1.2514 |
| 09:45 ET | 5443 | 1.22 |
| 09:48 ET | 2004 | 1.215 |
| 09:56 ET | 211 | 1.21 |
| 09:59 ET | 200 | 1.2299 |
| 10:06 ET | 3984 | 1.23 |
| 10:19 ET | 2134 | 1.23 |
| 10:28 ET | 2018 | 1.22 |
| 10:30 ET | 1000 | 1.2253 |
| 10:32 ET | 100 | 1.22 |
| 10:33 ET | 224 | 1.22 |
| 10:35 ET | 294 | 1.23 |
| 10:48 ET | 105 | 1.2379 |
| 10:55 ET | 100 | 1.24 |
| 11:06 ET | 1000 | 1.2464 |
| 11:18 ET | 1200 | 1.25 |
| 11:29 ET | 100 | 1.23 |
| 11:40 ET | 2603 | 1.24 |
| 11:44 ET | 200 | 1.24 |
| 11:51 ET | 1770 | 1.24 |
| 11:56 ET | 806 | 1.2594 |
| 12:05 ET | 2300 | 1.262 |
| 12:12 ET | 100 | 1.27 |
| 12:34 ET | 175 | 1.27 |
| 12:43 ET | 5200 | 1.262 |
| 12:56 ET | 100 | 1.26 |
| 01:57 ET | 143 | 1.27 |
| 02:13 ET | 200 | 1.28 |
| 02:51 ET | 205 | 1.27 |
| 03:09 ET | 5000 | 1.27 |
| 03:36 ET | 100 | 1.27 |
| 03:50 ET | 5000 | 1.2326 |
| 03:52 ET | 600 | 1.26 |
| 03:59 ET | 464 | 1.23 |
Apr 16, 2024
DJ BioRestorative Therapies Shares Rise 17% After FDA Clears Phase 2 Study Protocol Amendment, from 10:46AM ET on Tuesday Apr 16, 2024 by Dow Jones
10:46AM ET on Tuesday Apr 16, 2024 by Dow JonesBioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment, from 7:45AM ET on Tuesday Apr 16, 2024 by Dow Jones
7:45AM ET on Tuesday Apr 16, 2024 by Dow JonesBioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment, from 7:45AM ET on Tuesday Apr 16, 2024 by Dow Jones
7:45AM ET on Tuesday Apr 16, 2024 by Dow Jones
Apr 8, 2024
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease, from 7:45AM ET on Monday Apr 08, 2024 by Dow Jones
7:45AM ET on Monday Apr 08, 2024 by Dow JonesBioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease, from 7:45AM ET on Monday Apr 08, 2024 by Dow Jones
7:45AM ET on Monday Apr 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioRestorative Therapies Inc | 8.6M | -0.3x | --- |
Notable Labs Ltd | 8.8M | -0.3x | --- |
Virios Therapeutics Inc | 8.2M | -1.6x | --- |
Eterna Therapeutics Inc | 9.4M | -0.4x | --- |
Chromocell Therapeutics Corp | 9.2M | -1.2x | --- |
Akari Therapeutics PLC | 9.4M | -0.6x | --- |
Company Information
BioRestorative Therapies, Inc. is engaged in developing therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). The Company has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs.
Contact Information
- Headquarters
- 40 MARCUS DRIVEMELVILLE, NY, United States 11747
- Phone
- 631-760-8100
- Fax
- ---
Executives
- Chairman of the Board, President, Chief Executive Officer
- Lance Alstodt
- Chief Financial Officer
- Robert Kristal
- Vice President - Quality Assurance/Regulatory Compliance
- Robert Paccasassi
- Vice President - Research & Development, Secretary, Director
- Francisco Silva
- Independent Director
- Nickolay Kukekov
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.6M |
|---|---|
Revenue (TTM) | $145.8K |
Shares Outstanding | 6.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.54 |
Book Value | $2.45 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 59.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -10,439.49% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
